Philip joins P95 as Pharmacovigilance Expert

It is our pleasure to announce that Dr Philip has joined P95 as Pharmacovigilance Expert.

Before joining P95, Philip (Phil) worked for over 20 years at the UK regulatory authority, the MHRA, where he led on vaccine pharmacovigilance. In this position Phil led many national and EU benefit-risk reviews of vaccines and medicines, as well as the review and approval process of the safety and risk management aspects of several vaccine and other biologicals marketing authorization applications. Phil was also active in the EU pharmacovigilance network and co-authored several vaccine pharmacovigilance guidelines such as the Good Vigilance Practice (GVP) modules on vaccines and biologics.

In addition to his regulatory role, Phil was also working closely with the UK public health authorities with whom he planned and held oversight over several risk management strategies related to the implementation of new vaccination programs, notably the 2009 pandemic flu programme, HPV vaccine, Meningitis B vaccine and, most recently, the COVID-19 vaccine campaign.

Phil holds a Bachelors degree in Pharmacology and Physiology and a PhD in Physiology.  He has co-authored many peer-reviewed articles; including several vaccine safety related papers in lead journals such as the Lancet and BMJ.

Thomas Verstraeten, CEO of P95 said: We are very excited to have Phil join us at this key moment in our company’s development.  Boosted by the large demands related to the COVID-19 pandemic, P95 has more than doubled its workforce over the last year and we count on experts like Phil to help us maintain the highest quality standards in our work.  Phil will help us further develop the size and skills of the rapidly expanding PV group within P95 but also give valuable support to the other colleagues involved in any pre- or post-authorization risk management planning.






P95, Leuven-based company specialized in epidemiology and pharmacovigilance, acquires Rotterdam-based Pallas health research and consultancy (Pallas).

Thomas Verstraeten, CEO of P95: Thanks to our extensive expertise in the development and implementation of vaccines, we experienced a sharp increase in projects and associated growth during the COVID-19 pandemic. To allow us to further support the growing market of vaccination, we are looking for partners to sustain our growth. Pallas is a company with very similar expertise and clientele to P95. Judith van den Bosch and her team have developed a well-functioning and profitable company, close to the values of P95. This acquisition fits perfectly into our strategy to become an even more relevant player in the growing vaccination market.

Judith van den Bosch, founder of Pallas: Merging with P95 is a logical step in the development of Pallas. The types of projects and employees of Pallas and P95 are very similar, but the two companies also complement each other in terms of the research areas and customers.  By becoming part of P95, I expect to be able to offer my team more opportunities and, together with P95, to be able to increase our impact clout now and in the future.

About P95
P95 was founded in 2011 by the current CEO, Thomas Verstraeten, former Vice President of the vaccine department and head of pharmacovigilance and epidemiology at GSK. In 2021, P95 has become an important player on the international stage of vaccine development, working for almost all major vaccine producers and international institutions such as the World Health Organization, the Gates Foundation and the European Commission. With a team of epidemiologists, statisticians, medical writers and analysts, P95 conducts epidemiological studies to help clients plan the development of new vaccines and monitor the effects of vaccines on the market. P95 also contributes to the development of COVID-19 vaccines and follow-up of their effectiveness after approval.  (

About Pallas
Pallas health research and consultancy BV was founded in 1999 by Judith van den Bosch. Over the past 20 years, Pallas has become an established player on the contract research market in the field of epidemiology and health research. Pallas’ team consists of 12 epidemiologists with expertise in various disease fields and research methods. Pallas is based in Rotterdam, but has an international customer portfolio with a wide variety of organizations from the health sector and pharmaceutical industry. Pallas has been recognized in recent years for conducting systematic literature research in various contexts, such as clinical guidelines or drug development. (






P95 appoints Stefaan as Chief Financial Officer

Press Release – July 1st 2020


P95 appoints Stefaan as Chief Financial Officer

P95, a service provider specialized in epidemiology, statistics and pharmacovigilance, is happy to announce that Stefaan will be joining the management team as Chief Financial Officer, effective July 6th this year.

Stefaan is a senior executive with a proven track record in leading fast-growing companies.  He previously held CFO positions at MobileXpense and Luciad, two belgian PE backed software companies.  He began his career as an financial auditor at PwC.

Stefaan is a qualified accountant and holds a Masters’ degree in Applied Economics.

Thomas Verstraeten, managing director of P95 said ‘I’m very excited to have Stefaan join our management team. Stefaan brings us a wealth of experience in supporting SMEs like ours to achieve steady growth. Since we started 9 years ago we have seen our turnover, number of staff, diversity of expertise and scope of work significantly increase. Stefaan will be key in supporting us further on this growth trajectory and enabling us to better serve our ever increasing number of clients.’ Stefaan stated, ‘I look forward to joining P95 and leading its finance organization to contribute to P95’s future success as the company is rapidly scaling its operations.’

About P95.

P95 is a service provider, headquartered in Leuven, Belgium with staff in various European locations.  Specialised in the epidemiology of infectious diseases and vaccine development, P95 supports public health agencies, vaccine manufacturers and others in setting up, conducting and analysing epidemiological studies and real world data as well as pharmacovigilance related activities. P95 is part of several Innovative Medicines Innovation (IMI) projects, including DRIVE ( and VITAL ( and has recently won an award for 196 thousand Euros from VLAIO to support its development of artificial intelligence to better interpret real life data in support of vaccine development.  P95 staff have co-authored over 65 peer reviewed publications.

European Project "Vaccines and InfecTious diseases in the Ageing popuLation" (VITAL) Kicks Off

P95 participates in VITAL!

After ADVANCE and DRIVE, this is the third IMI project in which P95 can showcase its capabilities. Colleagues Kaatje Bollaerts and Estelle Méroc even coordinate the work on the P95 side.

Read the article >

P95 supports HEARTSAVER

We care about people, public health and global health, and how we contribute it!

When Heartsaver contacted us to tell about their project, we immediately decided to join the project in Leuven as a sponsor. The Automated External Defibrillator (AED) has been installed in the Diestsestraat 163 , in Leuven.

P95 was invited  to join the official inauguration and we also got the chance to join a First Aid course. Check out their website: Heartsaver vzw !

DRIVE: A call for tenders

Measuring brand-specific influenza vaccine effectiveness in EU/EEA: A call for tenders

The IMI project DRIVE (Development of Robust and Innovative Vaccine Effectiveness) has issued a call for tenders to evaluate influenza vaccine effectiveness (IVE) by vaccine type and brand. Its purpose is to support the sharing of existing IVE data and to establish new IVE studies, including novel and innovative approaches. The call is open to any European organization, institution or network and closes on 10 June 2018; both existing and new IVE study sites may apply.

For more information, please contact 

or visit:

ECCMID 2018 - DRIVE is searching for new collaborators

DRIVE is searching for new collaborators for the next influenza season, to develop robust tools to measure influenza  vaccine effectiveness.

The DRIVE project for brand-specific influenza vaccine effectiveness studies will be presented at the ECCMID conference in Madrid, on 21-24 April 2018.

Find out more about DRIVE (Development of Robust and Innovative Vaccine Effectiveness)

P95 in Beijing

In collaboration with the Developing Countries Vaccine Manufacturers Network,  P95 has given a 4-day PharmacoVigilance training workshop in Beijing. 

Over 60 participants took part, representing vaccine manufacturers from China and various other countries in South East Asia.